SHPH - Shuttle Pharmaceuticals Holdings, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

SHPH

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

NASDAQ

$3.54

▼ DOWN 8.76% (-0.34)

KEY STATISTICS

Market Cap$2.07 M

52w High$55.90

52w Low$2.58

Dividend Yield—

Frequency—

P/E-0.16

Volume55.27K

Shares Out.585.13K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christopher Robert Cooper

COMPENSATION 2026

Salary$193,549

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$193,549

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 31, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

SPLIT RECORD

DATE	TYPE	RATIO
2026-06-11	Reverse	1:10
2025-06-16	Reverse	1:25
2024-08-13	Reverse	1:8

PRICE

$3.54 ▼ DOWN 8.76% (−$0.34)

OVERLAYS

About Shuttle Pharmaceuticals Holdings, Inc.

https://www.shuttlepharma.com ↗

Shuttle Pharmaceuticals develops and commercializes cancer radiosensitizers like Ropidoxuridine and Doranidazole for brain, soft tissue, pancreatic, lung, and liver cancers.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT SHUTTLE PHARMACEUTICALS HOLDINGS, INC. IS KNOWN FOR

Ropidoxuridine

Shuttle Pharmaceuticals' lead Phase II drug is an oral radiation sensitizer aimed at improving radiation therapy outcomes for brain tumor and sarcoma patients.